Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 20/20 | 0.85 |
| ▸ | CDK6 | Q00534 | 19/20 | 0.85 |
| ▸ | CSF1R | P07333 | 11/20 | 0.84 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.84 |
| ▸ | CDK2 | P24941 | 5/20 | 0.84 |
| ▸ | CCNK | O75909 | 2/20 | 0.84 |
| ▸ | CDK9 | P50750 | 2/20 | 0.84 |
| ▸ | CDK7 | P50613 | 1/20 | 0.84 |
| ▸ | CCNH | P51946 | 1/20 | 0.84 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.84 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.84 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30631152 | 1.00 | CDK4 (0.85) | CDK4CDK6CSF1RCCNA2CDK2 | |
| Hydrochloric Acid SCHEMBL30119836 | 0.99 | CDK4 (0.84) | CDK4CDK6CSF1RCCNA2CDK2 | |
| Hydrochloric Acid SCHEMBL21245863 | 0.99 | CDK4 (0.84) | CDK4CDK6CSF1RCCNA2CDK2 | |
| SCHEMBL21245673 | 0.96 | CDK4 (0.81) | CDK4CDK6CSF1RCCNA2CDK2 | |
| SCHEMBL21245810 | 0.92 | CDK4 (1.00) | CDK4CDK6CSF1RCCNA2CDK2 | |
| Inixaciclib SCHEMBL29780787 | 0.92 | CDK4 (1.00) | CDK4CDK6CSF1RCCNA2CDK2 | |
| Inixaciclib SCHEMBL21245766 | 0.92 | CDK4 (1.00) | CDK4CDK6CSF1RCCNA2CDK2 | |
| Inixaciclib SCHEMBL30063971 | 0.91 | CDK4 (0.98) | CDK4CDK6CSF1RCCNA2CDK2 | |
| Inixaciclib SCHEMBL21245586 | 0.91 | CDK4 (0.98) | CDK4CDK6CSF1RCCNA2CDK2 | |
| SCHEMBL30631020 | 0.90 | CDK4 (0.76) | CDK4CDK6CSF1RCCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050577-A1 | CDK INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN (SHANGHAI) PHARMA ENG CO., LTD. (CN) | 2024-02-15 | — | — | US | disclosed |
| WO-2023205892-A1 | CDK INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023205892-A1 | CDK INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-11-02 | — | — | WO | disclosed |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230000876-A1 | TREATING CANCERS WITH A CYCLIN-DEPENDENT KINASE INHIBITOR | NUVATION BIO INC (US) | 2023-01-05 | — | — | US | disclosed |
| WO-2022261643-A1 | TREATING CANCERS WITH A CYCLIN-DEPENDENT KINASE INHIBITOR | NUVATION BIO INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | NUVATION BIO INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | NUVATION BIO INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20190248774-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-08-15 | — | — | US | disclosed |
| US-20190248774-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | CDK6, CDK4, CDK9 | CDK4 2/4885CDK6 1/4885CSF1R 3721/4885 |
| US-20190248774-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | CDK4 1/4885CDK6 2/4885CSF1R 4272/4885 |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | CDK4 1/4885CDK6 2/4885CSF1R 4272/4885 |
| US-20230000876-A1 | TREATING CANCERS WITH A CYCLIN-DEPENDENT KINASE INHIBITOR | CDK4, CDK6, CDK2 | CDK4 1/4885CDK6 2/4885CSF1R 2503/4885 |
| US-20240050577-A1 | CDK INHIBITORS AND PHARMACEUTICAL USES THEREOF | CDKL1, CDKL2, CDKL3 | CDK4 13/4885CDK6 4/4885CSF1R 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.